Anti-inflammatory drugs dont prevent memory loss in older adultsMay 13th, 2008 - 3:58 pm ICT by admin
Washington, May 13 (ANI): A new study has shown that anti-inflammatory drugs naproxen and celecoxib may not improve cognitive function in older adults with a family history of Alzheimers disease.
The researchers also found that naproxen may have a slightly detrimental effect.
Inflammatory processes may play a role in Alzheimers disease and other neurodegenerative disorders, as well as in the decline of cognitive (thinking, learning and memory) function in older adults, according to background information in the article.
Consistent with this hypothesis, observational studies have shown an association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and a lower risk of Alzheimers disease, the authors write.
The ADAPT (Alzheimers Disease Anti-Inflammatory Prevention Trial) Research Group conducted a randomized clinical trial involving 2,117 individuals age 70 and older with a family history of Alzheimers disease.
From March 2001 to December 2004, 617 took 200 milligrams of the NSAID celecoxib twice daily, 596 took 220 milligrams of naproxen sodium twice daily and 904 took placebo. Each year, the study participants took seven tests assessing cognitive function that were added into one global summary score. Treatments were halted in December 2004 because another study found increased cardiovascular risks associated with celecoxib.
The ADAPT cognitive function results through six months after study treatment cessation do not show a protective effect with the use of NSAIDs and may suggest that cognitive scores are lower, the authors write.
The global summary scores, which combine the results from seven individual tests in the cognitive assessment battery, were significantly lower over time for naproxen, but not for celecoxib, compared with placebo, the add.
There are several explanations for the difference between these findings and those of previous observational trials, the authors note. Because observational trials do not assign participants to treatment groups but analyze existing behavior, additional factors that were not measured may have confounded or affected the results.
In addition, the findings of this trial may apply only to celecoxib and naproxen and not to other anti-inflammatories, such as ibuprofen. Finally, NSAIDs may be protective only when given several years before the time when cognitive function would have begun to decline.
Continued follow-up of trial participants, even after cessation of treatment, appears warranted to investigate treatment effects with respect to the timing of exposure, the authors write.
However, for now we suggest that naproxen and celecoxib should not be used for the prevention of Alzheimers disease, they conclude. (ANI)
- Common painkillers increase risk of heart problems: Study - Jan 12, 2011
- Widely used arthritis pill shows promise against skin cancer - Dec 03, 2010
- DHA 'fish oil' supplements 'not useful for those with mild Alzheimer's' - Nov 03, 2010
- Anti-inflammatory drugs reduce effectiveness of antidepressants - Apr 26, 2011
- Ibuprofen more effective than paracetamol for period pain - Jan 20, 2010
- Painkillers double risk of miscarriage: Study - Sep 07, 2011
- Painkillers shoot up death risk in heart attacks - May 10, 2011
- Anti-depressants ease osteoarthritis pain - Mar 23, 2012
- Turmeric 'the right spice' to fight colon cancer - Mar 03, 2011
- Painkillers could kill heart attack survivors early - Sep 11, 2012
- Bugs can convert drugs into deadly toxins - Dec 05, 2011
- Aspirin, ibuprofen offer no protection against skin cancer - Feb 16, 2010
- Turmeric can fight colon cancer - Mar 03, 2011
- Celebrex shows potential in preventing some skin cancers - Dec 01, 2010
- Tumeric derivative found promising in tendinitis - Aug 11, 2011
Tags: 200 milligrams, anti inflammatory drugs, assessment battery, cardiovascular risks, cognitive assessment, cognitive function, cognitive thinking, global summary, individuals age, inflammatory prevention trial, inflammatory processes, learning and memory, memory function, neurodegenerative disorders, non steroidal anti inflammatory drugs, older adults, randomized clinical trial, study participants, summary score, summary scores